advisorsecurities master

TPSTTempest Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key
22692
Ticker
TPST
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2021-06-28
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
TPST

Detail

Enriched 2026-08-14 20:47

Market cap
$19,335,087.31
Shares outstanding (class)
15,979,411
Shares outstanding (weighted)
15,979,411
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
4
Location
BRISBANE, CA
Description

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data